 The SV-BR-1-GM regimen will be tailored to accommodate the dosing regimen of the immunotherapy, but cannot be more frequent than every 2 weeks, except when approved by the Investigator in consultation with the Sponsor. After the first year of therapy, consideration should be given to decreasing the frequency of therapy monthly, every 6 weeks, etc. by the PI in consultation with the Sponsor. Note that hormonal therapy e.g., aromatase inhibitors is permitted if ongoing, but may be added while the patient is on this study only with the Sponsors approval. 